Skip to main content

Currently Skimming:

B7. Comments on Session II
Pages 183-188

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.


From page 183...
... USE OF MIFEPRISTONE AND PROSTAGLANDIN FOR FIRST-TRIMESTER ABORTION Need for Medical Supervision The first scientific issue relates to the implied danger of mifepristone. A recurrent theme in review articles to date is that mifepristone for abortion requires "strict medical supervision" and that hospital facilities are required.
From page 184...
... The European model of abortion provision is unlikely to be compatible with the United States health care delivery system because of the cumbersome requirement for multiple visits. In the United States, abortion services are currently limited largely to metropolitan areas, with more than 80 percent of U.S.
From page 185...
... At the present time, a single visit to an abortion provider poses a hardship for many women in the United States. If mifepristone abortion is offered only in the European model, the service will be so cumbersome and expensive that many U.S.
From page 186...
... This has not received much attention in the United States. Premedication 36 to 48 hours before beginning an induction abortion cuts the time in half, and the important advantage here is that this now makes induction abortion
From page 187...
... such as the tradihonal laminaria. Lamicet which a polyvinyl alcohol sponge impregnated with magnesium sulfate.
From page 188...
... Second, I think we all concur that better dose-finding studies are needed. Third, we need a way to come up with a less cumbersome regimen for administering RU 486, particularly in conjunction with a prostaglandin analogue.


This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More information on Chapter Skim is available.